Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot, three viruses? new vaccine trial targets RSV, hMPV, and PIV3 in seniors

NCT ID NCT06604767

Vaccine Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 study tests a new vaccine that aims to protect against three respiratory viruses at once: RSV, hMPV, and PIV3. The trial involves 390 adults aged 60 and older and will check if the vaccine is safe and helps the body produce antibodies. Different combinations and doses are being compared to find the best approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Combined vaccine targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3)
What this could lead to
If successful, this could lead to a single vaccine that protects older adults from three common respiratory viruses, potentially reducing severe illness and hospitalizations.
What could go wrong
This is an early Phase 1 trial with only 390 participants, so safety and immune response are still being tested. It may not work as hoped, and side effects like injection site reactions or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

390 people

The number who actually took part.

Started

Sep 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 60 years or older on the day of inclusion (means from the means from the day of the 60th birthday). * Informed consent form (ICF) has been signed and dated * A female participant is eligible to participate if she is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: -Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives. Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metapneumovirus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

parainfluenza infectious disease Paramyxoviridae infectious disease parainfluenza virus type 3 infectious disease prevention target respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metapneumovirus infection Parainfluenzae virus infection Respiratory syncytial virus infection

Contacts and locations

Locations

  • Investigational Site Number : 0360001

    Botany, New South Wales, 2019, Australia

  • Investigational Site Number : 0360002

    Camberwell, Victoria, 3124, Australia

  • Investigational Site Number : 0360003

    Bayswater, Victoria, 3153, Australia

  • Investigational Site Number : 0360004

    Miranda, New South Wales, 2228, Australia

  • Investigational Site Number : 0360005

    Kanwal, New South Wales, 2259, Australia

  • Investigational Site Number : 0360006

    Blacktown, New South Wales, 2148, Australia

  • Investigational Site Number : 0360008

    Herston, Queensland, 4006, Australia

  • Investigational Site Number : 0360009

    Brookvale, New South Wales, 2100, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.